China Biopharma Inc. (CBI) is a biopharmaceutical company, that is engaged in introduction and marketing of human vaccines and other pharmaceutical products. It has two operational segments. One segment, consisting of CBL and its subsidiaries provides bio-pharmaceutical products. The product protifilo of the company includes human vaccines against influenza (flu), epidemic hemorrhagic fever (HF), and japanese encephalitis (JE). The other segment it consists of China Quantum Communication Limited (CQCL). The company has a dedicated division for its research and development activities, currently it has following products in its pipeline, Group A ,C, Y, W135 meningococcal polysaccharide, avian (ÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€¦Ã¢â‚¬Å“Bird FluÃƒÆ’Ã‚Â¢ÃƒÂ¢Ã¢â‚¬Å¡Ã‚Â¬Ãƒâ€šÃ‚Â) H5N1 virus and other allergy vaccine. CBI is headquartered in Hangzhou, China.